Drug Trial Radar · NCT02013544
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
Last checked: Nov 20, 2026Latest source record: Jun 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
558
Actual
Start
Feb 2014
Primary completion
Jan 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- EndoCeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the ICH E1 guideline requirements.
Conditions
- Vaginal Atrophy
Interventions
PlaceboDrug
Prasterone (DHEA)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal SmearTime frame: Baseline and Week 12
- Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal SmearTime frame: Baseline and Week 12
- Change From Baseline to Week 12 in Vaginal pHTime frame: Baseline and Week 12
- Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of DyspareuniaTime frame: Baseline and Week 12
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
EndoCeutics site # 39
Montgomery, Alabama
EndoCeutics site # 14
Tucson, Arizona
EndoCeutics site # 21
Sacramento, California
EndoCeutics site # 83
San Diego, California
EndoCeutics site # 30
San Diego, California
EndoCeutics site # 36
Denver, Colorado
EndoCeutics site # 52
Denver, Colorado
EndoCeutics site # 45
Boynton Beach, Florida
EndoCeutics site # 60
Lake Worth, Florida
EndoCeutics site # 54
North Miami, Florida
EndoCeutics site # 80
West Palm Beach, Florida
EndoCeutics site # 23
Atlanta, Georgia
EndoCeutics site # 55
Wichita, Kansas
EndoCeutics site # 86
Louisville, Kentucky
EndoCeutics site # 27
Lutherville, Maryland
EndoCeutics site # 87
Lawrenceville, New Jersey
EndoCeutics site # 81
Plainsboro, New Jersey
EndoCeutics site # 05
Cleveland, Ohio
EndoCeutics site # 15
Columbus, Ohio
EndoCeutics site # 75
Philadelphia, Pennsylvania
EndoCeutics site # 84
Corpus Christi, Texas
EndoCeutics site # 82
Houston, Texas
EndoCeutics site # 03
Norfolk, Virginia
EndoCeutics site # 76
Seattle, Washington
EndoCeutics site # 85
Burlington, Ontario, Canada
EndoCeutics site # 69
Corunna, Ontario, Canada
EndoCeutics site # 68
Sarnia, Ontario, Canada
EndoCeutics site # 73
Waterloo, Ontario, Canada
EndoCeutics site # 04
Drummondville, Quebec, Canada
EndoCeutics site # 12
Montreal, Quebec, Canada
EndoCeutics site # 79
Pointe-Claire, Quebec, Canada
EndoCeutics site # 02
Québec, Quebec, Canada
EndoCeutics site # 01
Québec, Quebec, Canada
EndoCeutics site # 77
Québec, Quebec, Canada
EndoCeutics site # 78
Québec, Quebec, Canada
EndoCeutics site # 18
Saint Romuald, Quebec, Canada
EndoCeutics site # 74
Sherbrooke, Quebec, Canada
EndoCeutics site # 67
Victoriaville, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.